Impedimed Limited Announces Director’s Interest Change

The latest update is out from Impedimed Limited ( (AU:IPD) ).

Impedimed Limited announced a change in the director’s interest, with Ms. Janelle Delaney acquiring additional ordinary shares. The acquisition was part of a compensation arrangement where shares were issued in lieu of 30% of her director fees for the quarter ended March 31, 2025. This move reflects the company’s strategy to align director compensation with shareholder interests, potentially impacting the company’s governance and financial strategies.

More about Impedimed Limited

Impedimed Limited operates in the medical technology industry, specializing in non-invasive medical devices. The company focuses on providing solutions for the measurement of fluid status and body composition, primarily targeting healthcare providers and patients managing conditions such as lymphedema, heart failure, and chronic kidney disease.

YTD Price Performance: -44.44%

Average Trading Volume: 72,592

Technical Sentiment Signal: Buy

Current Market Cap: $44.18M

Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.